Early Detection of Diabetic Nephropathy Based on Urinary and Serum Biomarkers: An Updated Systematic Review

Overview

Journal Adv Biomed Res

Specialty Biomedical Engineering

Date 2024 Dec 24

PMID 39717256

Authors

Farzaneh Karimi

Mostafa Moazamfard

Rasul Taghvaeefar

Shahla Sohrabipour

Aghdas Dehghani

Reza Azizi

Negar Dinarvand

Affiliations

Soon will be listed here.

Abstract

Diabetic nephropathy (DN) is a leading cause of chronic kidney disease (CKD) and end-stage renal disease worldwide, particularly among individuals with type 2 diabetes mellitus (T2DM). Early detection and intervention are crucial in slowing the progression of DN and improving patient outcomes. Traditional diagnostic methods, such as the measurement of albuminuria and serum creatinine, often fail to detect early renal damage because structural kidney damage may occur before albumin excretion. This systematic review aims to evaluate the diagnostic value of various urinary and serum biomarkers in the early detection of DN in patients with T2DM. A comprehensive literature search was conducted using databases such as PubMed, Scopus, and Web of Science. We only considered studies involving human populations for inclusion in our analysis. Animal and studies were excluded from our review. Our analysis of 17 observational studies identified several key serum biomarkers, such as netrin-1, osteopontin, adiponectin, and specific cytokines (e.g., IL-6, IL-8), which show significant promise for early detection of DN. Urinary biomarkers, including neutrophil gelatinase-associated lipocalin (NGAL), transferrin, N-acetyl-β-D-glucosaminidase (NAG), and various cytokines, have also proven to be reliable indicators. The combination of both serum and urinary biomarkers may enhance diagnostic accuracy and enable earlier intervention. Additionally, incorporating genetic and mRNA markers could provide a more comprehensive approach to early DN detection. Implementing these biomarkers in clinical practice could significantly improve outcomes for patients with DN by facilitating early diagnosis and timely management.

Citing Articles

Augmented Intrarenal and Urinary Angiotensinogen in Diabetic Nephropathy: The Role of Isoflavones.

Kamiyama M, Iijima K, Okuzawa R, Kawata R, Kimura A, Shinohara Y Int J Mol Sci. 2025; 26(4).

PMID: 40003909 PMC: 11855285. DOI: 10.3390/ijms26041443.

References

Lee S, Choi M . Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr Nephrol. 2014; 30(7):1063-75. PMC: 4305495. DOI: 10.1007/s00467-014-2888-2. View

Arroyave F, Montano D, Lizcano F . Diabetes Mellitus Is a Chronic Disease that Can Benefit from Therapy with Induced Pluripotent Stem Cells. Int J Mol Sci. 2020; 21(22). PMC: 7698772. DOI: 10.3390/ijms21228685. View

Jiang H, Guan G, Zhang R, Liu G, Liu H, Hou X . Increased urinary excretion of orosomucoid is a risk predictor of diabetic nephropathy. Nephrology (Carlton). 2009; 14(3):332-7. DOI: 10.1111/j.1440-1797.2008.01053.x. View

Zachwieja J, Soltysiak J, Fichna P, Lipkowska K, Stankiewicz W, Skowronska B . Normal-range albuminuria does not exclude nephropathy in diabetic children. Pediatr Nephrol. 2010; 25(8):1445-51. DOI: 10.1007/s00467-010-1443-z. View

Assal H, Tawfeek S, Rasheed E, El-Lebedy D, Thabet E . Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes. 2013; 6:7-13. PMC: 3738377. DOI: 10.4137/CMED.S12633. View

Yang Y, Xiao L, Li J, Kanwar Y, Liu F, Sun L . Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Med Hypotheses. 2013; 81(2):274-8. PMC: 3706533. DOI: 10.1016/j.mehy.2013.04.031. View

Borges F, Reis L, Schor N . Extracellular vesicles: structure, function, and potential clinical uses in renal diseases. Braz J Med Biol Res. 2013; 46(10):824-30. PMC: 3854311. DOI: 10.1590/1414-431X20132964. View

Zhou L, Yao D, Zhao S, Jiang Y, Lu W . Clinical Characterization of Serum Docosahexaenoic Acid and Its Relationship With Inflammation Factors in Patients With Diabetic Nephropathy. Iran J Kidney Dis. 2018; 12(2):91-98. View

Ni X, Gu Y, Yu H, Wang S, Chen Y, Wang X . Serum Adipocyte Fatty Acid-Binding Protein 4 Levels Are Independently Associated with Radioisotope Glomerular Filtration Rate in Type 2 Diabetic Patients with Early Diabetic Nephropathy. Biomed Res Int. 2018; 2018:4578140. PMC: 5994326. DOI: 10.1155/2018/4578140. View

10.

Pisitkun T, Shen R, Knepper M . Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004; 101(36):13368-73. PMC: 516573. DOI: 10.1073/pnas.0403453101. View

11.

Uslu S, Efe B, Alatas O, Kebapci N, Colak O, Demirustu C . Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. J Nephrol. 2005; 18(5):559-67. View

12.

Jain S, Rajput A, Kumar Y, Uppuluri N, Arvind A, Tatu U . Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J Assoc Physicians India. 2005; 53:513-20. View

13.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

14.

Gross J, de Azevedo M, Silveiro S, Canani L, Caramori M, Zelmanovitz T . Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2004; 28(1):164-76. DOI: 10.2337/diacare.28.1.164. View

15.

Perkins B, Ficociello L, Roshan B, Warram J, Krolewski A . In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 2009; 77(1):57-64. PMC: 3725722. DOI: 10.1038/ki.2009.399. View

16.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

17.

Harkin C, Cobice D, Brockbank S, Bolton S, Johnston F, Strzelecka A . Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients. Front Endocrinol (Lausanne). 2022; 13:887237. PMC: 9276980. DOI: 10.3389/fendo.2022.887237. View

18.

Al-Hazmi S, Gad H, Alamoudi A, Eldakhakhny B, Binmahfooz S, Alhozali A . Evaluation of early biomarkers of renal dysfunction in diabetic patients. Saudi Med J. 2020; 41(7):690-697. PMC: 7502923. DOI: 10.15537/smj.2020.7.25168. View

19.

Musante L, Tataruch D, Holthofer H . Use and isolation of urinary exosomes as biomarkers for diabetic nephropathy. Front Endocrinol (Lausanne). 2014; 5:149. PMC: 4176463. DOI: 10.3389/fendo.2014.00149. View

20.

Lin Z, Dai S, Zhao J, Jiang Y . Application of urinary N-acetyl-β-D-glucosaminidase combined with serum retinol-binding protein in early detection of diabetic nephropathy. World J Diabetes. 2023; 14(6):883-891. PMC: 10294068. DOI: 10.4239/wjd.v14.i6.883. View